BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1777 related articles for article (PubMed ID: 1530790)

  • 21. Effects of three low-dose oral contraceptive formulations on lipid metabolism.
    Bertolini S; Elicio N; Cordera R; Gapitanio GL; Montagna G; Croce S; Saturnino M; Balestreri R; De Cecco L
    Acta Obstet Gynecol Scand; 1987; 66(4):327-32. PubMed ID: 2962417
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clinical and metabolic study of a new pill containing 20 mcg ethinylestradiol plus 0.150 mg desogestrel.
    Fioretti P; Fruzzetti F; Navalesi R; Ricci C; Miccoli R; Cerri M; Orlandi MC; Melis GB
    Contraception; 1987 Mar; 35(3):229-43. PubMed ID: 2956055
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Desogestrel- and levonorgestrel-containing oral contraceptives have different effects on urinary excretion of prostacyclin metabolites and serum high density lipoproteins.
    Ylikorkala O; Kuusi T; Tikkanen MJ; Viinikka L
    J Clin Endocrinol Metab; 1987 Dec; 65(6):1238-42. PubMed ID: 2960690
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The effect of a desogestrel-containing oral contraceptive on glucose tolerance and leptin concentrations in hyperandrogenic women.
    Nader S; Riad-Gabriel MG; Saad MF
    J Clin Endocrinol Metab; 1997 Sep; 82(9):3074-7. PubMed ID: 9284746
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effect of four combined oral contraceptives on blood pressure in the pill-free interval.
    Nichols M; Robinson G; Bounds W; Newman B; Guillebaud J
    Contraception; 1993 Apr; 47(4):367-76. PubMed ID: 8508666
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Evaluation of a new triphasic oral contraceptive in private practice.
    Ellsworth HS; Ayerst RI; Harris JW; Stone RA; Anderson AE; Jones TL; Curtis MK
    Contraception; 1986 Nov; 34(5):435-42. PubMed ID: 3102161
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Plasma glucose and insulin levels in women using a levonorgestrel-containing triphasic oral contraceptive for three months.
    Spellacy WN; Ellingson AB; Kotlik A; Tsibris JC
    Contraception; 1988 Jul; 38(1):27-35. PubMed ID: 3139358
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A two-year clinical study of the effects of two triphasic oral contraceptives on plasma lipids.
    Kakis G; Powell M; Marshall A; Woutersz TB; Steiner G
    Int J Fertil Menopausal Stud; 1994; 39(5):283-91. PubMed ID: 7820162
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Six-month carbohydrate metabolism studies in women using oral contraceptives containing gestodene and ethinyl estradiol.
    Spellacy WN; Tsibris JC; Hunter-Bonner DL; Smalling S; Chez RA; Angel JL; O'Brien WF
    Contraception; 1992 Jun; 45(6):533-9. PubMed ID: 1617962
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Desogestrel, norgestimate, and gestodene: the newer progestins.
    Kaplan B
    Ann Pharmacother; 1995; 29(7-8):736-42. PubMed ID: 8520092
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Serum pharmacokinetics of orally administered desogestrel and binding of contraceptive progestogens to sex hormone-binding globulin.
    Bergink W; Assendorp R; Kloosterboer L; van Lier W; Voortman G; Qvist I
    Am J Obstet Gynecol; 1990 Dec; 163(6 Pt 2):2132-7. PubMed ID: 2147817
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Influence of gestodene and desogestrel as components of low-dose oral contraceptives on the pharmacokinetics of ethinyl estradiol (EE2), on serum CBG and on urinary cortisol and 6 beta-hydroxycortisol.
    Hammerstein J; Daume E; Simon A; Winkler UH; Schindler AE; Back DJ; Ward S; Neiss A
    Contraception; 1993 Mar; 47(3):263-81. PubMed ID: 8462317
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Carbohydrate metabolism in Gynanovlar 21 and Lyndiol 2.5 users.
    Kamal I; Zaki K; Rashad S
    Egypt Popul Fam Plann Rev; 1972 Jun; 5(1):67-77. PubMed ID: 12256028
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effect of duration of low-dose oral contraceptive administration on carbohydrate metabolism.
    Wynn V
    Am J Obstet Gynecol; 1982 Mar; 142(6 Pt 2):739-46. PubMed ID: 6801979
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Metabolic parameter, bleeding, and weight changes in U.S. women using progestin only contraceptives.
    Mainwaring R; Hales HA; Stevenson K; Hatasaka HH; Poulson AM; Jones KP; Peterson CM
    Contraception; 1995 Mar; 51(3):149-53. PubMed ID: 7621683
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Omitting the first oral contraceptive pills of the cycle does not automatically lead to ovulation.
    Elomaa K; Rolland R; Brosens I; Moorrees M; Deprest J; Tuominen J; Lähteenmäki P
    Am J Obstet Gynecol; 1998 Jul; 179(1):41-6. PubMed ID: 9704763
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Low-dose oral contraceptives and acquired resistance to activated protein C: a randomised cross-over study.
    Rosing J; Middeldorp S; Curvers J; Christella M; Thomassen LG; Nicolaes GA; Meijers JC; Bouma BN; Büller HR; Prins MH; Tans G
    Lancet; 1999 Dec; 354(9195):2036-40. PubMed ID: 10636369
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effect of the progestogens, gestodene, 3-keto desogestrel, levonorgestrel, norethisterone and norgestimate on the oxidation of ethinyloestradiol and other substrates by human liver microsomes.
    Back DJ; Houlgrave R; Tjia JF; Ward S; Orme ML
    J Steroid Biochem Mol Biol; 1991 Feb; 38(2):219-25. PubMed ID: 2004043
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clinical aspects of three new progestogens: desogestrel, gestodene, and norgestimate.
    Chez RA
    Am J Obstet Gynecol; 1989 May; 160(5 Pt 2):1296-300. PubMed ID: 2524163
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comparison of contraceptive acceptability of levonorgestrel and ethinyl oestradiol administered in one three-phasic (Trionetta) and one monophasic (Neovletta) version.
    Carlborg L
    Contraception; 1983 May; 27(5):439-52. PubMed ID: 6349925
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 89.